Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to expect.

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...

Wall Street expects a year-over-year increase in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports results for the quarter ended June 2025. While this widely-known consensus ...

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...

Piper Sandler analyst David Westenberg maintained a Hold rating on Neogen today and set a price target of $5.00. The company’s shares closed yesterday at $5.12. Take advantage of TipRanks Premium at ...

The stock's fall snapped a five-day winning streak.

IBM's stock price is down today as the tech giant beat Wall Street expectations for revenue and profit, but missed on this ...

Figma raised the proposed price range for its U.S. initial public offering on Monday and is now aiming for a valuation of $18 ...